← board
CPRX
distress 0/10 · well-funded / low risk$31.490%today0% from 52w high
Lead: Duchenne Muscular Dystrophy · est. market ~$4B (approx, global)
Revenue
$149M
Liquidity
$756M
Runway
—
Shares 1y
0%
Price & events
+28.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.4%
1M
+22.8%
3M
+30.5%
6M
+49.9%
1Y
+85.9%
2Y
+451.5%
5Y
+792.1%
All
Overview
- Market Cap
- $3.85B
- Volume
- 0
- 52 Week Range
- $19.13 – $31.50
- Total Shares
- 122.38M
- Float Shares
- 115.58M
- Short %
- 6.78%
- % Held by Insiders
- 5.57%
- % Held by Institutions
- 89.76%
- Beta
- 0.74
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 10
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)Merger closing expected in Q3 2026SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-16partnershipFTC granted early termination of HSR waiting period for merger with Angelini PharmaSEC 8-K
- 2026-05-06partnershipEntered into definitive merger agreement with Angelini PharmaSEC 8-K
- January 12, 2026conferencedata presentationsecondaryPresented at 44th Annual JP Morgan Healthcare ConferenceSEC 8-K
- 2025-08-26partnershipFIRDAPSE · Settled patent litigation with Lupin; license to market generic beginning February 2035.SEC 8-K
- early 2025regulatory submissionFiled (NDA/BLA)AGAMREE (vamorolone) · Regulatory submission to Health Canada for AGAMREE in DMDSEC 8-K
- 2025-01-08partnershipFIRDAPSE · Entered into settlement agreement with Teva granting license to market generic amifampridine no earlier than February 25, 2035.SEC 8-K
- 2024-11-06partnershipAGAMREE · Exclusive agreement with KYE for Canadian commercial rights to AGAMREESEC 8-K
- 2024-07-24partnershipAGAMREE (vamorolone) · Exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for Canadian rightsSEC 8-K
Approved drugs (4)
- AGAMREEVAMOROLONE2023 · Prescription
- FIRDAPSEAMIFAMPRIDINE PHOSPHATE2018 · Prescription
- FYCOMPAPERAMPANEL2016 · Prescription
- FYCOMPAPERAMPANEL2012 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-28HC Wainwright & Co.Buy → Neutral
- 2026-05-08CitigroupBuy → Neutral
- 2026-05-07Stephens & Co.Overweight → Equal-Weight
- 2026-03-03CitigroupBuy
- 2025-11-07CitigroupBuy
- 2025-03-03BairdOutperform
Competitors — Duchenne Muscular Dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
- SLDBSolid Biosciences Inc.$777M · D4
- RGNXREGENXBIO Inc.$508M · D7
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- PEPGPepGen Inc.$133M · D6
Recent news
- 2026-07-22Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple - TechStock²
- 2026-07-21Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent - TechStock²
- 2026-07-20Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now? - webull.com
- 2026-07-18Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now? - simplywall.st
- 2026-07-17Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout - Stock Titan
- 2026-07-17Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
- 2026-07-17Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
- 2026-07-17Angelini deal converts CATALYST PHARMACEUTICALS (NASDAQ: CPRX) officer equity to cash - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.